Background: Primary hepatic angiosarcoma (PHA) is a rare and aggressive solid tumor, with high rates of local recurrence and distant metastasis, and poor prognosis. There are no established treatment guidelines for PHA. Case presentation: A 78-year-old asymptomatic man with PHA that was successfully treated with pazopanib plus PD-1 inhibitor and RetroNectin-activated killer cells (RAK cells). After one month of treatment, there was a clear reduction in the size and number of the liver metastases; and after nearly 15months, most of the lesions were stable, no new lesions had developed, and the side effect of treatment was minor. Conclusion: Pazopanib, PD-1 inhibitor and RAK cells could serve as a potential option for the treatment of advanced PHA.
Mendeley helps you to discover research relevant for your work.
CITATION STYLE
Qiao, Y., Yang, J., Liu, L., Zeng, Y., Ma, J., Jia, J., … Wang, Y. (2018). Successful treatment with pazopanib plus PD-1 inhibitor and RAK cells for advanced primary hepatic angiosarcoma: A case report. BMC Cancer, 18(1). https://doi.org/10.1186/s12885-018-3996-3